Editor's Note: This study was funded by the Commonwealth of Pennsylvania Department of Health. Co-author Jolene Brown, M.D., was supported by a National Institutes of Health/National Institute of Diabetes and Digestive and Kidney Diseases grant. Please see the article for additional information, including other authors, author contributions and affiliations, financial disclosures, funding and support, etc.
Editorial: The State of Obesity and Obesity Research
"Class II obesity (body mass index [BMI] of more than 35) and class III obesity (BMI of 40 or more) is a prevalent condition that adversely affects health," according to Donna H. Ryan, M.D. of Pennington Biomedical Research Center, Louisiana State University System, Baton Rouge, and Robert Kushner, M.D., M.S., of Northwestern University Feinberg School of Medicine, Chicago, in an accompanying editorial.
"Severe obesity is a prevalent public health problem, disproportionately affecting women and minorities. There is still much to learn about the mechanisms underlying differing risk and treatment outcomes between populations. Optimal treatment approaches for class II and class III obesity are underexplored, while payment approaches for interventions known to work have yet to be adopted."
"Additional rigorous research, such as the clinical trial by Goodpaster et al, are needed to unravel the causes, identify prevention strategies, and develop the best treatments for obesity," they conclude.
(JAMA.2010; 304 : doi:10.1001/JAMA.2010.1531. Available pre-embargo to the media at www.jamamedia.org.)
Editor's Note: Please see the article for additional information, author contributions and affiliations, financial disclosures, etc.
|Contact: Amy Dugas Rose|
JAMA and Archives Journals